BioCentury | Apr 27, 2018
Company News

Nektar, Takeda partner to evaluate combo therapy for cancer

...and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to evaluate Nektar's NKTR-214 in combination with Takeda's TAK-659...
...to start next half and will evaluate NKTR-214 every three weeks with once-daily doses of TAK-659...
...resulting in increased PD-1 expression on T cells and NK cells in the tumor microenvironment. TAK-659...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

...Safety, change in IgG levels in 23 healthy volunteers 3483 Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) TAK-659...
BioCentury | May 16, 2017
Distillery Therapeutics

Dermatology

...hematologic malignancies and in Phase I testing to treat RA. Takeda Pharmaceutical Co. Ltd. has TAK-659...
Items per page:
1 - 3 of 3